ANGLE plc

AGL

GB0034330679

Advanced Medical Equipment & Technology

Market Closed - London S.E. Other stock markets 16:35:08 18/09/2024 BST			5-day change	1st Jan Change
10.75 ^GBX	0.00%		-4.44%	-8.51%

08-23	Angle hails publication of research data in science journal	AN
08-22	Angle plc Announces the Publication of One of the Company's Clinical Studies That Was Submitted to the FDA for De Novo Regulatory Clearance of the Parsortix PC1 System	CI

Cet article est réservé aux membres

Déjà membre ?

Not a member ?

Free registration

Latest news about ANGLE plc

Angle hails publication of research data in science journal	08-23	AN
Angle plc Announces the Publication of One of the Company's Clinical Studies That Was Submitted to the FDA for De Novo Regulatory Clearance of the Parsortix PC1 System	08-22	CI
Angle plc Raises Funds via Open Offer of Shares	06-21	MT
Angle says open offer raises proceeds of GBP500,000	06-21	AN
EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows	06-05	AN
Angle plc to Raise GBP10.6 Million via Share Placing, Subscription, Open Offer	06-05	MT
ANGLE plc Reports Earnings Results for the Full Year Ended December 31, 2023	06-05	CI
ANGLE plc Provides Revenue Guidance for the First Half of 2024	06-05	CI
Bens Creek considers administration; Nexxen inks deal	05-16	AN
ANGLE plc Announces Publication of Study Using the Parsortix System	05-16	CI
Angle shares up on assay development deal with AstraZeneca	05-03	AN
Angle shares up on assay development deal with AstraZenaca	05-03	AN
Angle Plc to Supply Prostate Cancer Androgen Receptor Detection Assay to AstraZeneca	05-03	MT
AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal	05-03	AN
Confident start before US jobs data	05-03	AN
InterContinental Hotels makes first-quarter progress	05-03	AN
ANGLE plc Announces New Commercial Agreement with Large Pharma	05-03	CI
No record close for FTSE 100; mixed trade in US	04-24	AN
No record close for FTSE 100; mixed trade in US	04-24	AN
Angle plc to Develop New Cancer Assay in Deal with AstraZeneca	04-24	MT
Angle shares jump on supplier agreement with with AstraZeneca	04-24	AN
AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook	04-24	AN
Angle PLC Announces New Commercial Agreement with AstraZeneca PLC	04-24	CI
Angle granted patents in US and Europe for Cellkeep slide	04-22	AN
Angle plc Secures European Patent for CellKeep Technology	04-22	MT

ANGLE plc is a United Kingdom-based liquid biopsy company with circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. Its circulating tumor cell (CTC) harvesting technology known as the Parsortix PC1 System enables complete downstream analysis of the sample, including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. The Parsortix PC1 system is a medical device for the capture and harvest of intact CTCs from metastatic breast cancer (MBC) patient blood for user-validated analysis. Its commercial businesses focus on diagnostic products and clinical services. Its diagnostic products include the Parsortix system and associated consumables. Its services include custom made assay development and clinical trial testing for pharma. The Parsortix technology uses a microfluidic technology in the form of a single use cassette to capture and then harvest CTCs from whole blood.

Employees

Sector

Advanced Medical Equipment & Technology

Calendar

26/09/2024 - Q2 2024 Earnings Release

More about the company